|
1
|
Sidwell RW, Robins RK and Hillyard IW:
Ribavirin: an antiviral agent. Pharmacol Ther. 6:123–146. 1979.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shepherd J, Jones J, Hartwell D, Davidson
P, Price A and Waugh N: Interferon alpha (pegylated and
non-pegylated) and ribavirin for the treatment of mild chronic
hepatitis C: a systematic review and economic evaluation. Health
Technol Assess. 11:1–205. iii2007. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dueñas-González A, García-López P, Herrera
LA, Medina-Franco JL, González-Fierro A and Candelaria M: The
prince and the pauper. A tale of anticancer targeted agents. Mol
Cancer. 7:822008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Scheidel LM, Durbin RK and Stollar V:
Sindbis virus mutants resistant to mycophenolic acid and ribavirin.
Virology. 158:1–7. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Itoh O, Kuroiwa S, Atsumi S, Umezawa K,
Takeuchi T and Hori M: Induction by the guanosine analogue
oxanosine of reversion toward the normal phenotype of
K-ras-transformed rat kidney cells. Cancer Res. 49:996–1000.
1989.PubMed/NCBI
|
|
6
|
Jackson RC, Weber G and Morris HP: IMP
dehydrogenase, an enzyme linked with proliferation and malignancy.
Nature. 256:331–333. 1975. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zimmermann A, Gu JJ, Spychala J and
Mitchell BS: Inosine monophosphate dehydrogenase expression:
transcriptional regulation of the type I and type II genes. Adv
Enzyme Regul. 36:75–84. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nagai M, Natsumeda Y, Konno Y, Hoffman R,
Irino S and Weber G: Selective up-regulation of type II inosine
5′-monophosphate dehydrogenase messenger RNA expression in human
leukemias. Cancer Res. 51:3886–3890. 1991.PubMed/NCBI
|
|
9
|
Chen L and Pankiewicz KW: Recent
development of IMP dehydrogenase inhibitors for the treatment of
cancer. Curr Opin Drug Discov Devel. 10:403–412. 2007.PubMed/NCBI
|
|
10
|
Kentsis A, Topisirovic I, Culjkovic B,
Shao L and Borden KL: Ribavirin suppresses eIF4E-mediated oncogenic
transformation by physical mimicry of the 7-methyl guanosine mRNA
cap. Proc Natl Acad Sci USA. 101:18105–18110. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Borden KL and Culjkovic-Kraljacic B:
Ribavirin as an anticancer therapy: acute myeloid leukemia and
beyond? Leuk Lymphoma. 51:1805–1815. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Assouline S, Culjkovic B, Cocolakis E,
Rousseau C, Beslu N, Amri A, Caplan S, Leber B, Roy DC, Miller WH
Jr and Borden KL: Molecular targeting of the oncogene eIF4E in
acute myeloid leukemia (AML): a proof-of-principle clinical trial
with ribavirin. Blood. 114:257–260. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zagni C, Chiacchio U and Rescifina A:
Histone methyltransferase inhibitors: novel epigenetic agents for
cancer treatment. Curr Med Chem. 20:167–185. 2013. View Article : Google Scholar
|
|
14
|
Simon JA and Lange CA: Roles of the EZH2
histone methyltransferase in cancer epigenetics. Mutat Res.
647:21–29. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tan J, Yang X, Zhuang L, Jiang X, Chen W,
Lee PL, Karuturi RK, Tan PB, Liu ET and Yu Q: Pharmacologic
disruption of Polycomb-repressive complex 2-mediated gene
repression selectively induces apoptosis in cancer cells. Genes
Dev. 21:1050–1063. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wishart DS, Knox C, Guo AC, Cheng D,
Shrivastava S, Tzur D, Gautam B and Hassanali M: DrugBank: a
knowledgebase for drugs, drug actions and drug targets. Nucleic
Acids Res. 36:D901–D906. 2008. View Article : Google Scholar :
|
|
17
|
Willett P: Similarity-based virtual
screening using 2D fingerprints. Drug Discov Today. 11:1046–1053.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chemical Computing Group Inc., Montreal,
Quebec, Canada: Molecular Operating Environment (MOE), version
2011.10. http://www.chemcomp.com.
|
|
19
|
Willett P, Barnard JM and Downs GM:
Chemical similarity searching. J Chem Inf Comput Sci. 38:983–996.
1998. View Article : Google Scholar
|
|
20
|
Chan SL and Labute P: Training a scoring
function for the alignment of small molecules. J Chem Inf Model.
50:1724–1735. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bender A and Glen RC: Molecular
similarity: a key technique in molecular informatics. Org Biomol
Chem. 2:3204–3218. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Medina-Franco JL: Scanning
structure-activity relationships with structure-activity similarity
and related maps: from consensus activity cliffs to selectivity
switches. J Chem Inf Model. 52:2485–2493. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Robinson G, Parker M, Kranenburg TA, Lu C,
Chen X, Ding L, Phoenix TN, Hedlund E, Wei L, Zhu X, Chalhoub N,
Baker SJ, Huether R, Kriwacki R, Curley N, Thiruvenkatam R, Wang J,
Wu G, Rusch M, Hong X, Becksfort J, Gupta P, Ma J, Easton J,
Vadodaria B, Onar-Thomas A, Lin T, Li S, Pounds S, Paugh S, Zhao D,
Kawauchi D, Roussel MF, Finkelstein D, Ellison DW, Lau CC, Bouffet
E, Hassall T, Gururangan S, Cohn R, Fulton RS, Fulton LL, Dooling
DJ, Ochoa K, Gajjar A, Mardis ER, Wilson RK, Downing JR, Zhang J
and Gilbertson RJ: Novel mutations target distinct subgroups of
medulloblastoma. Nature. 488:43–48. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ryan RJ and Bernstein BE: Molecular
biology. Genetic events that shape the cancer epigenome. Science.
336:1513–1514. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shih AH, Abdel-Wahab O, Patel JP and
Levine RL: The role of mutations in epigenetic regulators in
myeloid malignancies. Nature Rev Cancer. 12:599–612. 2012.
View Article : Google Scholar
|
|
26
|
Kleer CG, Cao Q, Varambally S, Shen R, Ota
I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, Sabel MS,
Livant D, Weiss SJ, Rubin MA and Chinnaiyan AM: EZH2 is a marker of
aggressive breast cancer and promotes neoplastic transformation of
breast epithelial cells. Proc Natl Acad Sci USA. 100:11606–11611.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wagener N, Macher-Goeppinger S, Pritsch M,
Hüsing J, Hoppe-Seyler K, Schirmacher P, Pfitzenmaier J, Haferkamp
A, Hoppe-Seyler F and Hohenfellner M: Enhancer of zeste homolog 2
(EZH2) expression is an independent prognostic factor in renal cell
carcinoma. BMC Cancer. 10:5242010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Takawa M, Masuda K, Kunizaki M, Daigo Y,
Takagi K, Iwai Y, Cho HS, Toyokawa G, Yamane Y, Maejima K, Field
HI, Kobayashi T, Akasu T, Sugiyama M, Tsuchiya E, Atomi Y, Ponder
BA, Nakamura Y and Hamamoto R: Validation of the histone
methyltransferase EZH2 as a therapeutic target for various types of
human cancer and as a prognostic marker. Cancer Sci. 102:1298–1305.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chiang PK and Cantoni GL: Perturbation of
biochemical transmethylations by 3-deazaadenosine in vivo. Biochem
Pharmacol. 28:1897–1902. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Miranda TB, Cortez CC, Yoo CB, Liang G,
Abe M, Kelly TK, Marquez VE and Jones PA: DZNep is a global histone
methylation antagonist inhibitor that reactivates developmental
genes not silenced by DNA methylation. Mol Cancer Ther.
8:1579–1588. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee JK and Kim KC: DZNep, inhibitor of
S-adenosylhomocysteine hydrolase, down-regulates expression of
SETDB1 H3K9me3 HMTase in human lung cancer cells. Biochem Biophys
Res Commun. 438:647–652. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Margueron R, Li G, Sarma K, Blais A,
Zavadil J, Woodcock CL, Dynlacht BD and Reinberg D: Ezh1 and Ezh2
maintain repressive chromatin through different mechanisms. Mol
Cell. 32:503–518. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Simon JA and Kingston RE: Occupying
chromatin: Polycomb mechanisms for getting to genomic targets,
stopping transcriptional traffic, and staying put. Mol Cell.
49:808–824. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kökény S, Papp J, Weber G, Vaszkó T,
Carmona-Saez P and Oláh E: Ribavirin acts via multiple pathways in
inhibition of leukemic cell proliferation. Anticancer Res.
29:1971–1980. 2009.PubMed/NCBI
|
|
35
|
Pettersson F, Yau C, Dobocan MC,
Culjkovic-Kraljacic B, Retrouvey H, Puckett R, Flores LM, Krop IE,
Rousseau C, Cocolakis E, Borden KL, Benz CC and Miller WH Jr:
Ribavirin treatment effects on breast cancers overexpressing eIF4E,
a biomarker with prognostic specificity for luminal B-type breast
cancer. Clin Cancer Res. 17:2874–2884. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kosaka T, Nagamatsu G, Saito S, Oya M,
Suda T and Horimoto K: Identification of drug candidate against
prostate cancer from the aspect of somatic cell reprogramming.
Cancer Sci. 104:1017–1026. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Medina-Franco JL, Giulianotti MA, Welmaker
GS and Houghten RA: Shifting from the single to the multitarget
paradigm in drug discovery. Drug Discov Today. 18:495–501. 2013.
View Article : Google Scholar : PubMed/NCBI
|
